| ²é¿´: 575 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
·ÒëÇóÖú
|
||
| What about the ways of DLL4 targeting? As mentioned above, one of them is specific targeting using anti-DLL4 antibodies. Unlike ¦Ã-secretase inhibitors, anti-DLL4 antibodies did not induce gastrointestinal toxicity. They have no discernible impact on goblet cell differentiation or crypt progenitor cell proliferation. Hoey et al. found that selective antihuman antibody 21M18 inhibited expression of Notch target genes including HES1 and ATOH1, which in effect caused a low level of malignant cell proliferation . |
» ²ÂÄãϲ»¶
272·Ö²ÄÁÏ×ÓÇóµ÷¼Á
ÒѾÓÐ31È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
²ÄÁϹ¤³ÌÈÕÓÉúÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
¹ã¶«Ê¡ 085601 329·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
¿¼Ñе÷¼Á
ÒѾÓÐ25È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
µ÷¼Á »¯Ñ§ 307
ÒѾÓÐ17È˻ظ´
²ÄÁÏÀà284µ÷¼Á
ÒѾÓÐ45È˻ظ´
368Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
295·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´

ÓÀÔ¶µÄNO.1
½û³æ (ÎÄ̳¾«Ó¢)
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
3Â¥2014-02-23 16:01:53
RXMCDM
°æÖ÷ (ÎÄ̳¾«Ó¢)
- ·ÒëEPI: 530
- Ó¦Öú: 401 (˶ʿ)
- ¹ó±ö: 1.908
- ½ð±Ò: 38947.6
- É¢½ð: 4908
- ºì»¨: 88
- ɳ·¢: 4
- Ìû×Ó: 11453
- ÔÚÏß: 1355.6Сʱ
- ³æºÅ: 2739168
- ×¢²á: 2013-10-20
- ÐÔ±ð: GG
- רҵ: Ò»°ã¹ÜÀíÀíÂÛÓëÑо¿·½·¨ÂÛ
- ¹ÜϽ: ÂÛÎÄ·Òë
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2014-02-24 15:34:00
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2014-02-24 15:34:00
|
DLL4°ÐÏò·½Ê½ÊÇÔõôÑùµÄ£¿ÈçÉÏËùÊö£¬ÆäÖÐÖ®Ò»ÊÇÌØ¶¨µÄ¿¹DLL4¿¹Ìå°ÐÏò¡£Óë¦Ã-·ÖÃÚøÒÖÖÆÒò×Ó²»Í¬£¬¿¹DLL4¿¹Ìå²»ÓÕµ¼Î¸³¦µÀ¶¾ÐÔ¡£ËûÃǶԱ״ϸ°û·Ö»¯»òÒþÎÑ×æÏ¸°ûµÄÔöֳûÓÐÃ÷ÏÔµÄÓ°Ïì¡£HoeyµÈ·¢ÏÖ¿¹ÈË¿¹Ìå21M18Ñ¡ÔñÐÔÒÖÖÆ°üÀ¨HES1»ùÒòºÍATOH1»ùÒòÔÚÄÚµÄNotch°Ð»ùÒò£¬ÒÖÖÆ°Ð»ùÒòʵ¼ÊÉÏÔì³ÉÁ˶ñÐÔϸ°ûÔöֳˮƽµÍÏ¡£ ¹©²Î¿¼£¡ |

2Â¥2014-02-22 01:18:42













»Ø¸´´ËÂ¥